Cambridge Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
Cambridge Advisors's ARKG Position: Q3 2026 in Review
Cambridge Advisors increased its ARK Genomic Revolution ETF (ARKG) stake by 3.5% in Q3 2026, buying an estimated $20K and bringing the position to 13,021 shares worth $706K. The position accounts for 0.12% of the portfolio, ranked #101.
Cambridge Advisors first reported a position in ARKG in Q1 2018 and has held it in 21 quarters since. The position peaked at $2.08M in Q2 2021. 316 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.
- Cambridge Advisors held 13,021 shares of ARK Genomic Revolution ETF worth $706K as of Q3 2026.
- Cambridge Advisors bought 445 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $20K.
- ARK Genomic Revolution ETF made up 0.12% of Cambridge Advisors's portfolio in Q3 2026, its #101 holding.
- Cambridge Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 21 quarters since.
- Cambridge Advisors's ARK Genomic Revolution ETF position peaked at $2.08M in Q2 2021.
- 316 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.
Based on Cambridge Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.